Ovarian Cancer Trial, Recruiting NCT05910294 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT05910294
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 or older
  • Women who have been diagnosed with breast cancer that is hormone receptor positive, at an early to moderate stage (stage 0 through stage 3)
  • Women who are still having periods or are approaching menopause, meaning they have either been pregnant, had at least one period in the last 24 months, or currently have or recently had an IUD (a type of birth control device placed in the uterus)
  • Women who are currently using, or are about to start, a treatment that reduces the activity of their ovaries
  • Women who do not currently have vaginal dryness, pain during intercourse, or discomfort, and who score 3 or below on specific symptom rating scales (confirm with trial site)

Who may not be able to join:

  • Women who have gone through menopause and have not had a period for 2 or more years
  • Women who score 4 or higher on the vaginal symptom rating scales used in this trial (confirm with trial site)
  • Women who are currently using treatments for vaginal dryness or discomfort — such as vaginal estrogen, moisturizers, or suppositories — unless they have stopped using them for at least 4 weeks before joining

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Shari Goldfarb, MD, Memorial Sloan Kettering Cancer Center

Phone: 646-888-5080

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 June 2023
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants with a score of 4 or greater in VAS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov